Top Page
Nuchev Pty Ltd
(Sydney:NUC)
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
Nuchev Pty Ltd Business Overview & Revenue Model
Nuchev Pty Ltd Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.34M | 8.79M | 9.72M | 10.90M | 17.76M |
| Gross Profit | 3.63M | 1.66M | 2.78M | 3.20M | 5.64M |
| EBITDA | -7.18M | -8.57M | -10.88M | -12.40M | -10.09M |
| Net Income | -7.32M | -8.81M | -11.81M | -13.74M | -12.40M |
Balance Sheet | |||||
| Total Assets | 20.09M | 15.32M | 17.75M | 28.31M | 27.51M |
| Cash, Cash Equivalents and Short-Term Investments | 7.61M | 7.49M | 5.13M | 14.53M | 9.44M |
| Total Debt | 322.85K | 284.14K | 154.12K | 286.33K | 386.26K |
| Total Liabilities | 5.34M | 2.51M | 1.92M | 1.62M | 2.23M |
| Stockholders Equity | 14.75M | 12.82M | 15.83M | 26.69M | 25.28M |
Cash Flow | |||||
| Free Cash Flow | -3.74M | -3.38M | -11.62M | -9.86M | -10.76M |
| Operating Cash Flow | -3.73M | -3.26M | -11.61M | -9.49M | -10.69M |
| Investing Cash Flow | -2.19M | -126.83K | -914.20K | 411.90K | -53.94K |
| Financing Cash Flow | 6.06M | 5.78M | -118.28K | 14.16M | 9.88M |
Nuchev Pty Ltd Technical Analysis
Nuchev Pty Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | AU$2.23B | -0.28 | -14.39% | 11.12% | 7.38% | -60.19% | |
49 Neutral | AU$22.67M | ― | -33.40% | ― | -13.09% | -139.06% | |
45 Neutral | AU$37.41M | ― | ― | 4.22% | -199.40% | ||
44 Neutral | AU$22.00M | ― | -47.74% | ― | 43.14% | 51.35% | |
44 Neutral | €30.48M | ― | -23.00% | ― | -2.14% | 11.40% | |
40 Underperform | AU$18.30M | ― | -240.42% | ― | 14.41% | 76.26% |
Nuchev Pty Ltd Corporate Events
Nuchev Limited announced the issuance of 333,333 fully paid ordinary shares without disclosure to investors, in compliance with the Corporations Act 2001. This move indicates Nuchev’s adherence to regulatory obligations and its strategic financial maneuvering, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the application for the quotation of 333,333 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of July 3, 2025. This move involves the issuance, transfer, or reclassification of securities resulting from options being exercised or other convertible securities being converted, reflecting the company’s strategic financial maneuvers to potentially enhance its market presence and shareholder value.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited announced that H&S Group has achieved its second-year performance hurdle under their distribution agreement, leading to the vesting of Tranche 2 performance options. This achievement allows Nuchev to issue up to 8,749,000 shares to H&S Investments, potentially injecting $1.9 million into the company. This capital boost will enhance Nuchev’s financial flexibility, supporting its strategic growth plans. The company appreciates H&S Group’s continued support, which aligns with Nuchev’s objectives for expansion.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the cessation of 705,586 share rights due to the lapse of conditional rights that were not satisfied. This development may affect the company’s issued capital and could have implications for its stakeholders, as it reflects on the company’s current operational conditions and market positioning.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Ltd has announced the appointment of Meng Zhang, also known as Leo, as a new director effective from May 26, 2025. The initial director’s interest notice indicates that Meng Zhang currently holds no securities in the company, either as a registered holder or otherwise, and has no interests in any contracts related to the company. This appointment reflects a strategic decision by Nuchev Ltd, potentially impacting its governance and future direction.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has appointed Meng Zhang, known as Leo, as a Non-Executive Director to its Board. Leo Zhang brings over a decade of cross-border experience in brand management, international trade, and corporate governance, with a strong background in the Asia-Pacific consumer goods market. His leadership at H&S Global Brand Center has been instrumental in the success of several brands in China’s cross-border e-commerce sector and Southeast Asia. This appointment is expected to enhance Nuchev’s board skills and experience, supporting the company’s growth ambitions and recent strategic initiatives, including the acquisition of the bWellness business and partnerships with Brauer and H&S Brands.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has entered into an exclusive sales agency agreement with Brauer Natural Medicines Pty Ltd and H&S Brand Corporation Pty Ltd in Australia. This agreement focuses on selling certain products in Australian pharmacies, grocery stores, and health food stores, with the potential to expand into New Zealand. The collaboration aims to leverage Nuchev’s sales capabilities and Brauer’s established brand equity in the natural and complementary medicines sector, aligning with consumer demand for natural, clean-label products. This strategic move is expected to enhance Nuchev’s revenue and market presence in the complementary medicines sector.
Nuchev Pty Ltd reported significant sales growth following the launch of its Oli6® brand in Vietnam, contributing to a year-to-date sales increase of $1.1 million. The company’s acquisition of bWellness has also boosted group revenue by 215% compared to the previous corresponding period, with a notable increase in sales across the ANZ and China markets. The expansion into Vietnam and strategic partnerships in ANZ have positioned Nuchev for continued growth, with the company aiming to achieve breakeven.